CA3084034C - Covalent anesthetic-polymer conjugates for prolonged local anesthesia - Google Patents

Covalent anesthetic-polymer conjugates for prolonged local anesthesia Download PDF

Info

Publication number
CA3084034C
CA3084034C CA3084034A CA3084034A CA3084034C CA 3084034 C CA3084034 C CA 3084034C CA 3084034 A CA3084034 A CA 3084034A CA 3084034 A CA3084034 A CA 3084034A CA 3084034 C CA3084034 C CA 3084034C
Authority
CA
Canada
Prior art keywords
ttx
anesthetic
peg
pgs
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3084034A
Other languages
English (en)
French (fr)
Other versions
CA3084034A1 (en
Inventor
Daniel S. Kohane
Chao Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHILREN'S MEDICAL CENTER Corp
Original Assignee
CHILREN'S MEDICAL CENTER Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHILREN'S MEDICAL CENTER Corp filed Critical CHILREN'S MEDICAL CENTER Corp
Publication of CA3084034A1 publication Critical patent/CA3084034A1/en
Application granted granted Critical
Publication of CA3084034C publication Critical patent/CA3084034C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3084034A 2017-12-01 2018-12-03 Covalent anesthetic-polymer conjugates for prolonged local anesthesia Active CA3084034C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593784P 2017-12-01 2017-12-01
US62/593,784 2017-12-01
PCT/US2018/063573 WO2019109065A1 (en) 2017-12-01 2018-12-03 Covalent anesthetic-polymer conjugates for prolonged local anesthesia

Publications (2)

Publication Number Publication Date
CA3084034A1 CA3084034A1 (en) 2019-06-06
CA3084034C true CA3084034C (en) 2022-08-16

Family

ID=64734233

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3084034A Active CA3084034C (en) 2017-12-01 2018-12-03 Covalent anesthetic-polymer conjugates for prolonged local anesthesia

Country Status (7)

Country Link
US (2) US20210275678A1 (https=)
EP (1) EP3717017B1 (https=)
JP (2) JP7601375B2 (https=)
CN (1) CN111867633B (https=)
AU (1) AU2018375002B2 (https=)
CA (1) CA3084034C (https=)
WO (1) WO2019109065A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4090374A4 (en) * 2020-01-17 2024-10-09 Children's Medical Center Corporation MACROMOLECULAR PRODRUGS FOR LIGHT EMITTING DIODES AND THEIR USES
CN113805326A (zh) * 2021-09-18 2021-12-17 吉林大学 原位拉伸多光子激光共聚焦成像仪、实时原位三维观测共混聚合物内部结构的方法
US20250099421A1 (en) * 2023-09-27 2025-03-27 Relevium Medical Analgesic Therapeutics Based on conjugation of Biocompatible Polymers to Ion Channel Modulators
CN119345382B (zh) * 2024-12-23 2025-03-21 上海华之沃生物医药科技有限公司 替曲朵辛偶联物、制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001413A (en) 1973-06-12 1977-01-04 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition employing saxitoxin
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
WO1998051290A2 (en) * 1997-05-16 1998-11-19 Children's Medical Center Corporation Local anesthetic formulations comprising a site 1 sodium channel blocker combined with a second active agent
GB0218830D0 (en) * 2002-08-13 2002-09-18 Syngenix Ltd Anaesthetic conjugate
US20040228831A1 (en) * 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
US8980317B2 (en) * 2008-12-23 2015-03-17 Warsaw Orthopedic, Inc. Methods and compositions for treating infections comprising a local anesthetic
CN103932972A (zh) * 2009-03-30 2014-07-23 天蓝制药公司 聚合物-药剂缀合物、颗粒、组合物和相关使用方法
BR112013033239A2 (pt) * 2011-06-22 2016-09-06 Vyome Biosciences pró-farmácos de conjugado baseado em atifungicos e antibacterianos
WO2013163214A1 (en) * 2012-04-23 2013-10-31 The Children's Medical Center Corporation Formulations and methods for delaying onset of chronic neuropathic pain
TR201903411T4 (tr) * 2013-03-15 2019-04-22 Childrens Medical Ct Corp Uzun süreli lokal anestezi için neosaksitoksin kombinasyon formülasyonları.
US10449152B2 (en) * 2014-09-26 2019-10-22 Covidien Lp Drug loaded microspheres for post-operative chronic pain
CN106310289B (zh) * 2015-06-24 2020-10-13 天津键凯科技有限公司 一种聚乙二醇和麻醉药的结合物及其制备方法

Also Published As

Publication number Publication date
JP2024114970A (ja) 2024-08-23
AU2018375002B2 (en) 2021-11-11
JP7601375B2 (ja) 2024-12-17
JP2021505550A (ja) 2021-02-18
EP3717017B1 (en) 2026-02-25
WO2019109065A1 (en) 2019-06-06
AU2018375002A1 (en) 2020-07-02
CA3084034A1 (en) 2019-06-06
EP3717017A1 (en) 2020-10-07
US20250195671A1 (en) 2025-06-19
CN111867633A (zh) 2020-10-30
CN111867633B (zh) 2023-09-22
US20210275678A1 (en) 2021-09-09

Similar Documents

Publication Publication Date Title
US20250195671A1 (en) Covalent anesthetic-polymer conjugates for prolonged local anesthesia
Zhang et al. Long-acting hydrogel/microsphere composite sequentially releases dexmedetomidine and bupivacaine for prolonged synergistic analgesia
CA2843503C (en) Polymeric hyperbranched carrier-linked prodrugs
RU2554854C9 (ru) Биоразлагаемые нерастворимые в воде гидрогели на основе полиэтиленгликоля
Zhang et al. Sustained release of levobupivacaine from temperature-sensitive injectable hydrogel for long-term local anesthesia in postoperative pain management
IL190486A (en) Compounds of hydrophobic polymers undergoing glaciation and containing radical acid and their uses
CA2831469A1 (en) Biodegradable compositions suitable for controlled release
AU2011294295A1 (en) Crosslinked hyaluronic acid composition and self-crosslinking hyaluronic acid particles
CA2926169C (fr) Compositions a liberation continue a base d'acide hyaluronique, et leurs applications therapeutiques
EP3068373B1 (en) Aqueous based capsaicinoid formulations and methods of manufacture and use
US20090324741A1 (en) Injectable polymer-lipid blend
US20160279108A1 (en) Targeted mtor inhibitors
KR20190143555A (ko) 카토제닌 유도체를 포함하는 고분자 미셀, 히알루론산 하이드로겔 및 이의 제조방법 및 그 용도
Badawi et al. Pharmaceutical and medical aspects of hyaluronic acid–ketorolac combination therapy in osteoarthritis treatment: radiographic imaging and bone mineral density
EP3285761B1 (en) Parthenolide and its derivatives for use in the treatment of axonal damage
KR20230161453A (ko) 약제학적 조성물
US20250099598A1 (en) Analgesic Therapeutics Based on Conjugation of Biocompatible Polymers to Ion Channel Modulators
Pastukh et al. Injectable hyaluronic acid–metformin conjugate gel for sustained intra‐articular delivery and prevention of post‐traumatic osteoarthritis
CN121941510A (zh) 基于生物相容性聚合物与离子通道调节剂缀合的镇痛治疗剂
KR102062690B1 (ko) 이미다졸-폴리(유기포스파젠) 하이드로겔을 포함하는 척수 손상 예방 또는 치료용 조성물
Abdeltawab In Situ Gelling System to Provide Prolonged Postoperative Pain Relief Following Arthroplasty
WO2025068983A1 (en) Analgesic therapeutics based on conjugation of biocompatible polymers to ion channel modulators
Shao et al. A pH-responsive injectable hydrogel that modulates the inflammatory microenvironment for the treatment of osteoarthritis
Johnston Development of Dendritic Polymers as a Modular Drug Delivery Platform for Avascular Tissues
EP4724117A2 (en) Method of treating an articular condition or a condition of a bony canal

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200529

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241202

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241202

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251201

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251201